Sernova Corp

Sernova Corp

March 17, 2008 10:56 ET

Sernova Corp. Grants Stock Options

KELOWNA, BRITISH COLUMBIA--(Marketwire - March 17, 2008) - Sernova Corp. (the "Company") (TSX VENTURE:SVA) has granted incentive stock options to directors, officers and employees to purchase up to 375,000 common shares at $0.30 per share for a period of 5 years expiring March 14, 2013.

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin are estimated to be $25 billion annually.


Justin Leushner, President and CEO

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information